EUVIMEDEUVIMED entdecken
Crossref

A Case Study: Abiraterone-Induced Cardiac Arrhythmia and Heart Failure.

Janani sethupathy

Journal of MedVerse Research & Practice · 2024

DOI: 10.65188/nurexus.1008 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of MedVerse Research & Practice, 2024. Verfasst von Janani sethupathy. Die Arbeit nennt 17 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Advancements in cancer therapy have significantly improved survival rates, but with an aging population, the co-occurrence of cancer and cardiovascular disease has become increasingly common. Additionally, certain cancer treatments can cause myocardial damage and other cardiovascular complications. An 80-year-old male patient receiving treatment for late-stage prostate cancer requested a cardiac assessment after experiencing rapid heartbeat during nighttime hours. This case study examines the patient's situation and medical evaluation. His medical history included prostatectomy and orchiectomy performed 15 years earlier, along with hypertension and dyslipidemia. The patient had undergone treatment with abiraterone and goserelin for a period of two years. His current medication regimen included metoprolol, chlorthalidone, and rosuvastatin. During the physical examination, the patient exhibited high blood pressure, a slow heart rate, and irregular heartbeats were detected through listening to his heart sounds. The cardiac electrical activity assessment showed a slow heart rhythm, impaired conduction in the right bundle branch, the presence of a U wave, and a single premature beat originating above the ventricles. Blood tests indicated low potassium levels (2.9 mg/dL), while continuous heart monitoring over 24 hours detected persistent rapid atrial rhythm, particularly during nighttime hours. A cardiac ultrasound revealed a decrease in ejection fraction and enlargement of the left atrium and ventricle when compared to findings from two years earlier. As discontinuation of hormonal therapy was not an option, the treatment plan included switching to spironolactone, potassium supplementation, ramipril, and continued use of metoprolol. Within 30 days, the patient experienced symptomatic improvement, and his ventricular function recovered over six months. He lived for two more years before passing away due to complications from a fall. The cardiovascular effects of abiraterone are likely linked to its action on the adrenal glands, where it inhibits the synthesis of sex hormones and cortisol. This inhibition can lead to an overproduction of mineralocorticoids, resulting in hypokalemia, arrhythmias, and decreased cardiac function due to the lack of negative feedback from cortisol. Clinicians should be vigilant about these potential cardiovascular risks when managing patients receiving abiraterone. Keywords: abiraterone, cardio-oncology, heart failure, arrhythmia

Zitieren

APA

sethupathy, J. (2024). A Case Study: Abiraterone-Induced Cardiac Arrhythmia and Heart Failure. Journal of MedVerse Research & Practice. https://doi.org/10.65188/nurexus.1008

Vancouver

sethupathy J. A Case Study: Abiraterone-Induced Cardiac Arrhythmia and Heart Failure. Journal of MedVerse Research & Practice. 2024. doi:10.65188/nurexus.1008

BibTeX
@article{sethupathy2024,
  author = {sethupathy, Janani},
  title = {A Case Study: Abiraterone-Induced Cardiac Arrhythmia and Heart Failure},
  journal = {Journal of MedVerse Research & Practice},
  year = {2024},
  doi = {10.65188/nurexus.1008}
}
Kostenlos starten →